Revealing toxicity.In every cell.

We predict and explain how drugs cause toxicity, before they reach patients.

THE PROBLEM

Drug toxicity remains one of the biggest challenges in drug development

Most drug candidates fail during development. Many fail because toxicity signals appear too late to act. Earlier insight means safer and more affordable drugs.

88%
Clinical trial failure
rate
Nearly 9 out of 10 drugs entering clinical trials never reach patients
20-30%
Failures linked to toxicity
Safety concerns force termination
despite promising efficacy
$2.6B
Average cost to bring a drug to market
Capital required to bring each new
 FDA-approved medicine to market
WHAT DEEPCYTE DOES

A new way to understand cellular response

DeepCyte combines single-cell metabolomics with AI to detect metabolic changes within individual cells. This predicts toxicity and reveals mechanisms that remain invisible to conventional approaches.

Single-cell resolution
Our technology reveals what
 others don't see, in every cell.
AI driven prediction
Our human-centric models are trained to learn from large internal atlases.
Mechanistic insight
Our data science tools don't just flag risk, they show how cellular programs get rewired by drugs and how it can lead to toxicity.
Abstract gradient background with horizontal stripes blending pink, purple, and orange hues.

Our mission is to go beyond prediction — to reveal why drugs damage cells and deliver the mechanistic evidence that guides better decisions — before any patient is exposed.

Explainable Predictive Toxicology

Our vision is to put the 'why' into every prediction. We are doing so by building Digital Cells, human-first AI models that can predict toxicity and highlight mechanisms behind toxic effects, providing actionable information that can help make drugs safer.

Our enabling technology is world-leading high-throughput single-cell metabolomics, built on over 10+ years of work in leading academic institutions. It provides unprecedented resolution, sensitivity, and throughput.

By detecting shifts in metabolic markers, identifying characteristic metabolic patterns, and mapping drug-induced changes into metabolic networks, our AI-based solutions connect a prediction to its biological cause.

DeeImmuno is DeepCyte's first product. It goes beyond a toxicity risk score — it shows you what is happening inside immune cells, and why.

  • Predict toxicity types in immune cells at sublethal concentrations
  • Deconvolve co-existing toxicity types triggered by the same compound
  • Reveal mechanisms and metabolic rewiring triggered by drugs
  • Deliver actionable mechanistic insights, not just a risk score

Our award-winning team brings together leaders in science and business, with a track record of building field-defining products and companies.

Theodore Alexandrov

Theodore Alexandrov

CEO & Co-founder
Shawn Owens

Shawn Owens

COO & Co-founder
Henry Wong

Henry Wong

CFO
Carl Evertsz

Carl Evertsz

Chair of Board of Directors & Co-founder
Gina Wallbank

Gina Wallbank

VP Business Development & Sales
Jeany Delafiori

Jeany Delafiori

VP Business Development & Sales
Katja Ovchinnikova

Katja Ovchinnikova

VP Business Development & Sales
Theodore Alexandrov

Theodore Alexandrov

CEO & Co-founder
Shawn Owens

Shawn Owens

CTO & Co-founder
Henry Wong

Henry Wong

CFO
Carl Evertsz

Carl Evertsz

Chair of Board of Directors & Co-founder
Gina Wallbank

Gina Wallbank

VP Business Development & Sales
Jeany Delafiori

Jeany Delafiori

Product Manager & Data Scientist
Katja Ovchinnikova

Katja Ovchinnikova

Consulting AI Specialist